Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP) Exhibits Direct Antibacterial Activity Against Mycobacterium abscessus

References

• Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392–407. doi:10.1038/s41579-020-0331-132086501
   PubMed Web of Science ®Google Scholar
• Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;54(1):1900250. doi:10.1183/13993003.00250-201931221809
   PubMed Web of Science ®Google Scholar
• Koh WJ, Chang B, Jeong BH, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in south korea. Tuberc Respir Dis (Seoul). 2013;75(5):199–204. doi:10.4046/trd.2013.75.5.19924348667
   PubMedGoogle Scholar
• Griffith DE. Mycobacterium abscessus and antibiotic resistance: same as it ever was. Clin Infect Dis. 2019;69(10):1687–1689. doi:10.1093/cid/ciz07130689764
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao L, Mao Y, et al. Clinical efficacy and adverse effects of antibiotics used to treat mycobacterium abscessus pulmonary disease. Front Microbiol. 2019;10:1977. doi:10.3389/fmicb.2019.0197731507579
   PubMed Web of Science ®Google Scholar
• Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019;54(1):1801991. doi:10.1183/13993003.01991-201830880280
   PubMed Web of Science ®Google Scholar
• Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810–818. doi:10.1093/jac/dkr57822290346
   PubMed Web of Science ®Google Scholar
• Ardebili A, Talebi M, Azimi L, Rastegar Lari A. Effect of efflux pump inhibitor carbonyl cyanide 3-chlorophenylhydrazone on the minimum inhibitory concentration of ciprofloxacin in acinetobacter baumannii clinical isolates. Jundishapur J Microbiol. 2014;7(1):e8691. doi:10.5812/jjm.869125147654
   PubMed Web of Science ®Google Scholar
• Park YK, Ko KS. Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing acinetobacter baumannii by colistin. J Microbiol. 2015;53(1):53–59. doi:10.1007/s12275-015-4498-525557480
   PubMed Web of Science ®Google Scholar
• Wang Y, Venter H, Ma S. Efflux pump inhibitors: a novel approach to combat efflux-mediated drug resistance in bacteria. Curr Drug Targets. 2016;17(6):702–719. doi:10.2174/138945011666615100110394826424403
   PubMed Web of Science ®Google Scholar
• Rodrigues L, Parish T, Balganesh M, Ainsa JA. Antituberculosis drugs: reducing efflux=increasing activity. Drug Discov Today. 2017;22(3):592–599. doi:10.1016/j.drudis.2017.01.00228089787
   PubMed Web of Science ®Google Scholar
• Guo Q, Chen J, Zhang S, et al. Efflux pumps contribute to intrinsic clarithromycin resistance in clinical, mycobacterium abscessus isolates. Infect Drug Resist. 2020;13:447–454. doi:10.2147/IDR.S23985032104016
   PubMed Web of Science ®Google Scholar
• Rindi L. Efflux pump inhibitors against nontuberculous mycobacteria. Int J Mol Sci. 2020;21(12):4191. doi:10.3390/ijms21124191
   PubMed Web of Science ®Google Scholar
• CLSI. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard, 2nd. Clsi Document M24-A2. CLSI; 2011.
   Google Scholar
• Zhang S, Zou Y, Guo Q, et al. Ar-12 exhibits direct and host-targeted antibacterial activity toward mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64(8). doi:10.1128/AAC.00236-20.
   Web of Science ®Google Scholar
• Viljoen A, Raynaud C, Johansen MD, et al. Verapamil improves the activity of bedaquiline against mycobacterium abscessus in vitro and in macrophages. Antimicrob Agents Chemother. 2019;63(9). doi:10.1128/AAC.00705-19.
   Web of Science ®Google Scholar
• Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015;36(1):67–78. doi:10.1016/j.ccm.2014.10.00425676520
   PubMed Web of Science ®Google Scholar
• Ramis IB, Vianna JS, Silva Junior L, et al. In silico and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in mycobacterium abscessus. Tuberculosis (Edinb). 2019;118:101853. doi:10.1016/j.tube.2019.07.00431430699
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of mycobacterium massiliense from mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183(3):405–410. doi:10.1164/rccm.201003-0395OC20833823
   PubMed Web of Science ®Google Scholar
• Mougari F, Guglielmetti L, Raskine L, et al. Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Rev Anti Infect Ther. 2016;14(12):1139–1154. doi:10.1080/14787210.2016.123830427690688
   PubMed Web of Science ®Google Scholar
• Catherinot E, Roux AL, Macheras E, et al. Acute respiratory failure involving an r variant of mycobacterium abscessus. J Clin Microbiol. 2009;47(1):271–274. doi:10.1128/JCM.01478-0819020061
   PubMed Web of Science ®Google Scholar
• Nessar R, Reyrat JM, Davidson LB, Byrd TF. Deletion of the mmpl4b gene in the mycobacterium abscessus glycopeptidolipid biosynthetic pathway results in loss of surface colonization capability, but enhanced ability to replicate in human macrophages and stimulate their innate immune response. Microbiology (Reading). 2011;157(4):1187–1195. doi:10.1099/mic.0.046557-021292749
   PubMed Web of Science ®Google Scholar
• Pawlik A, Garnier G, Orgeur M, et al. Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent mycobacterium abscessus. Mol Microbiol. 2013;90(3):612–629. doi:10.1111/mmi.1238723998761
   PubMed Web of Science ®Google Scholar
• Rhoades ER, Archambault AS, Greendyke R, et al. Mycobacterium abscessus glycopeptidolipids mask underlying cell wall phosphatidyl-myo-inositol mannosides blocking induction of human macrophage TNF-α by preventing interaction with TLR2. J Immunol. 2009;183(3):1997–2007. doi:10.4049/jimmunol.080218119596998
   PubMed Web of Science ®Google Scholar
• Li B, Ye M, Zhao L, et al. Glycopeptidolipid genotype correlates with the severity of mycobacterium abscessus lung disease. J Infect Dis. 2020;221(Supplement_2):S257–S262. doi:10.1093/infdis/jiz47532176786
   PubMed Web of Science ®Google Scholar
• Rottman M, Catherinot E, Hochedez P, et al. Importance of t cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower mycobacterium abscessus in c57bl/6 mice. Infect Immun. 2007;75(12):5898–5907. doi:10.1128/IAI.00014-0717875636
   PubMed Web of Science ®Google Scholar
• Clary G, Sasindran SJ, Nesbitt N, et al. Mycobacterium abscessus smooth and rough morphotypes form antimicrobial-tolerant biofilm phenotypes but are killed by acetic acid. Antimicrob Agents Chemother. 2018;62(3). doi:10.1128/AAC.01782-17.
   Web of Science ®Google Scholar
• Ruger K, Hampel A, Billig S, et al. Characterization of rough and smooth morphotypes of mycobacterium abscessus isolates from clinical specimens. J Clin Microbiol. 2014;52(1):244–250. doi:10.1128/JCM.01249-1324197890
   PubMed Web of Science ®Google Scholar
• Ni W, Li Y, Guan J, et al. Effects of efflux pump inhibitors on colistin resistance in multidrug-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2016;60(5):3215–3218. doi:10.1128/AAC.00248-1626953203
   PubMed Web of Science ®Google Scholar
• Mlejnek P. Caspase-3 activity and carbonyl cyanide m-chlorophenylhydrazone-induced apoptosis in HL-60. Altern Lab Anim. 2001;29(3):243–249. doi:10.1177/02611929010290031311387021
   PubMed Web of Science ®Google Scholar
• Soutar MPM, Kempthorne L, Annuario E, et al. FBS/BSA media concentration determines CCCP’s ability to depolarize mitochondria and activate PINK1-PRKN mitophagy. Autophagy. 2019;15(11):2002–2011. doi:10.1080/15548627.2019.160354931060423
   PubMed Web of Science ®Google Scholar